As the co-founder of Seattle Genetic, Clay B. Siegall, Ph.D. is a leader in the pharmaceutical industry. He serves as the company’s President, Chairman of the Board, and Chief Executive Officer. He specializes in finding cures for cancer using antibody-drug conjugates. His first product to be approved by the FDA in 2011, Adcetris, is now helping cure people of lymphoma in the United States, Canada, and more than 63 other nations across the globe.
In addition to continuing to develop Adcetris as an effective cure for other forms of cancer than lymphoma, his company has several other drugs in their pipeline that are at different levels of development. As the leader of Seattle Genetics, Dr. Clay Seigall is instrumental in developing partnerships with other biotechnology companies. He partnered with the Japanese firm Takeda Pharmaceutical Company in order to bring Adcetris to markets around the world. He has also developed strategic licensing agreements with other companies including industry giants like Roche, Glaxosmith Kline, Pfizer, and Abbvie. Due to these partnerships, more than 20 antibody-drug conjugates are in clinical development. He has also been responsible for raising more than $1.2 billion for Seattle Genetics which includes it successful IPO in 2001.
Dr. Seigall worked in research and development for 10 years prior to co-founding Seattle Genetics, including positions at the National Cancer Institute as well as Bristol-Myers Squibb Pharmaceutical Research Institute which had brought him to the Seattle area in 1991. During his career, he has received a number of awards including being named by the Pacific Northwest Entrepreneur of the Year by Ernst & Young. He also holds 15 patents and has been the author of more than 70 publications.
When he was 24, Dr. Seigall lost his father to cancer. At the time, Oncologists didn’t have very many tools available to treat cancer. His father’s death inspired him to create tools that could be used to help patients defeat cancer and live longer and healthier lives. He believes one of his greatest strengths is collaborating with other industry leaders in order to develop effective cancer therapies that improve people’s lives.